Provider review, September 2026
Bioverse does something almost nothing else on this roster does: it publishes downloadable certificates of analysis at a named address, and both files are real. It also publishes exactly two of them, and neither is for a peptide.
Bioverse is not a paid partner; this link may earn a commission if that changes. Full disclosure.
The seller keeps a page whose whole purpose is certificates. It says it holds the latest certificates of analysis for its products, and it lists two: one for each of its two weight-loss compounds, each with a download link.
Both links were fetched. Both returned a success status, an actual PDF content type, and a file beginning with the bytes that identify a PDF. A nonsense filename on the same content network in the same run was refused, so the two successes are not an artefact of a server that answers for everything.
That makes this the strongest testing disclosure verified in this batch. It is also, read as a census rather than as an impression, a very short list. Two documents cover two products. The catalogue is much longer than two products.
The compounds this site compares — the injectable coenzyme and the injectable antioxidant — have no certificate on that page. A reader who arrives because the seller advertises certificates will not find one for the thing they are buying.
This is a shape that recurs across the roster and is worth naming. Several sellers here carry testing language, and on more than one of them it sits only on the weight-loss pages while the peptide pages carry none.
Bioverse is the sharpest version of it, because it is not language — it is documents, at a named URL, that a reader can open. The gap between what is documented and what is sold is therefore precisely measurable rather than a matter of tone.
Nothing about that is dishonest. The page says what it holds and holds what it says. But a comparison table that recorded this seller as one that publishes certificates, without recording which products they cover, would mislead every reader shopping for a peptide.
This site records the reachability and the scope as two separate facts, because on this seller they point in opposite directions.
Both peptide product pages print two figures side by side, the higher struck through. Further down each page the seller restates the lower figure as a per-month rate in a full sentence, and adds a claim about being cheaper than a dozen unnamed competitors.
No plan term is attached to either. There is no six-month condition, no annual prepayment, no first-month rate that lapses — three shapes that appear repeatedly elsewhere on this roster and that make a headline figure mean something other than a month.
The pages also print that a reader is only charged if a provider prescribes. That is a disclosure about when money moves, which is a different and more useful thing than a disclosure about how much.
The comparison to twelve leading brands names none of the twelve, so it is a claim about the market that a reader cannot check. This site does not repeat it as a fact.
The operating company is named in the footer of its own pages, and the clinical practice is named separately in the terms. Screening those names — not the domain — against the regulator's own warning-letter index returns a letter issued against this company by name.
It concerns unlawful online sale of unapproved and misbranded drugs through a telehealth channel. It is recorded on the row, it is linked, and it does not move this seller's score or position on any board here.
A domain search would have returned nothing, because the regulator indexes by entity and trading name. That is why the screen on this site is run against the company name and the brand name and never the website address.
No dispensing pharmacy is named anywhere, and no state coverage list is published, so neither of the two facts a buyer most often needs about fulfilment is available here.
Bioverse received an FDA warning letter issued September 2025. A warning letter discloses; it does not, on its own, disqualify a provider — see the trade-offs above for what this one concerned.
Trellis Vitality frames its program around body-composition tracking rather than scale weight, pairing NAD+, glutathione and tesamorelin with at-home biomarker panels and a 90-day re-test, and names its dispensing pharmacy, VialsRX in Houston, by address.
Read the full Trellis Vitality review
Trellis Vitality is not a paid partner; this link may earn a commission if that changes. Full disclosure.
Visit Trellis VitalityYes, at a named page, and both files resolve to real PDFs. The page lists exactly two documents and neither covers a peptide.
None is stated. Both product pages give a struck-through anchor and a per-month figure with no minimum, no prepayment and no first-month condition.
Yes. One was issued against the operating company by name over online sale of unapproved and misbranded drugs. It is disclosed on this seller's row and it does not affect its score or position here.
No. The operating company and the clinical practice are both named; the dispensing pharmacy is not.
The product pages say the price is lower than twelve leading brands and name none of them. This site does not repeat that as a fact.
Bioverse is not a paid partner; this link may earn a commission if that changes. Full disclosure.